Skip to main content
SpringerLink
Log in

Off-label oral anticoagulant doses increase risk of AEs

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II

References

  1. Steinberg BA, et al. Off-Label Dosing of Non-Vitamin K Antagonist Oral Anticoagulants and Adverse Outcomes: The ORBIT-AF II Registry. Journal of the American College of Cardiology 68: 2597-2604, No. 24, 20 Dec 2016. Available from: URL: http://doi.org/10.1016/j.jacc.2016.09.966.

    Article  CAS  PubMed  Google Scholar 

  2. Off-label oral anticoagulant doses increase risk of AEs 769: 22, 7 Jan 2016.

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Off-label oral anticoagulant doses increase risk of AEs. PharmacoEcon Outcomes News 769, 22 (2017). https://doi.org/10.1007/s40274-017-3658-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-017-3658-8

Search

Navigation